The Serum Institute of India, renowned for its pivotal role in global immunization efforts, is poised to significantly enhance the supply of its human papillomavirus (HPV) vaccine. With plans to offer the vaccine at reduced rates for a government-backed immunization campaign against the cancer-causing virus, the institute is set to make a substantial impact on public health initiatives.
Adar Poonawalla, the CEO of Serum Institute, outlined the institute’s commitment to expanding HPV vaccine accessibility, anticipating its integration into the government’s immunization program by year-end. The vaccine, priced at ₹2,000 ($24.13) in the private market, represents India’s first indigenous solution against HPV, a leading cause of cervical cancer globally.
Despite current capacity limitations, Poonawalla emphasized the overwhelming demand for the vaccine, highlighting the potential rollout of 50 million doses to meet both private and government procurement requirements. The government aims to administer the HPV vaccine to girls aged nine to 14 as part of a comprehensive strategy to combat cervical cancer, a prevalent health concern among women in India.
While contractual agreements with the government are pending, Poonawalla anticipates an initial procurement of 40 to 50 million doses through a tender process in December. Competition from other HPV vaccine manufacturers, including Merck & Co and GSK Plc, underscores the significance of Serum Institute’s commitment to this vital public health initiative.
Poonawalla anticipates a substantial reduction in vaccine costs for government procurement, potentially making it eight times cheaper than the current market rate. Despite operational constraints stemming from the pandemic-induced prioritization of COVID-19 vaccine production, Serum Institute remains steadfast in its efforts to scale up HPV vaccine manufacturing.
Looking ahead, Serum Institute is pursuing WHO pre-qualification for the HPV vaccine, paving the way for global distribution by 2026. The institute’s dedication to expanding vaccine access underscores its pivotal role in advancing public health initiatives and underscores its commitment to saving lives worldwide.
As Serum Institute continues to spearhead innovative solutions for disease prevention, its efforts in HPV vaccine production represent a significant stride towards achieving equitable healthcare access and combating cervical cancer on a global scale.
